This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Nadifloxacin is a topical fluoroquinolone used in the treatment of acne and topical bacterial skin infections.
- Generic Name
- Nadifloxacin
- DrugBank Accession Number
- DB12447
- Background
Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Nadifloxacin (DB12447)
- Weight
- Average: 360.385
Monoisotopic: 360.148535327 - Chemical Formula
- C19H21FN2O4
- Synonyms
- Nadifloxacin
- Nadifloxacino
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acne vulgaris •••••••••••• ••••• Treatment of Superficial skin infections •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareEstetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Nadifloxacin. Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Nadifloxacin. Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Nadifloxacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- D10AF05 — Nadifloxacin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Aryl fluorides / Benzenoids / Piperidines show 11 more
- Substituents
- Alcohol / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- quinolone antibiotic, hydroxypiperidine, pyridoquinoline, heteroarylpiperidine (CHEBI:31889)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6CL9Y5YZEQ
- CAS number
- 124858-35-1
- InChI Key
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)
- IUPAC Name
- 7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.0⁵,¹³]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
- SMILES
- CC1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCC(O)CC1
References
- General References
- TITCK Product Information: Nadixa (nadifloxacin) topical cream [Link]
- External Links
- PubChem Compound
- 4410
- PubChem Substance
- 347828688
- ChemSpider
- 4257
- BindingDB
- 50475222
- ChEBI
- 31889
- ChEMBL
- CHEMBL363449
- Wikipedia
- Nadifloxacin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Acne Vulgaris 1 somestatus stop reason just information to hide 3 Unknown Status Treatment Acne Vulgaris 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Cutaneous 1.000 g Cream Topical 1 % Cream Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.632 mg/mL ALOGPS logP 0.87 ALOGPS logP 1.84 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 6.13 Chemaxon pKa (Strongest Basic) 0.44 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 81.08 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 96.03 m3·mol-1 Chemaxon Polarizability 36.53 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.80843 predictedDeepCCS 1.0 (2019) [M+H]+ 189.54161 predictedDeepCCS 1.0 (2019) [M+Na]+ 196.70277 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:25 / Updated at May 27, 2021 02:58